Resumo

AFONSO-DE-LEON, José Alberto et al. Biomodulin T: a new therapeutic option against COVID-19. Rev.Med.Electrón. [online]. 2021, vol.43, n.6, pp. 1691-1696.  Epub 31-Dez-2021. ISSN 1684-1824.

To boost immunity in people with gradual deterioration of the immune system, caused by aging or suffering from different comorbidities, the Group of the Biotechnology and Pharmaceutical Industries of Cuba (Biotechnology Farma) has introduced the product Biomodulin T. This has also been used as part of the prevention protocol and for the treatment of patients positive to SARS-CoV-2. Thymus-dependent immunity, including T-cell immunity and antibody production, decreases with organ size in adults, which is known as “immunosenescence.” Biomodulin T is a diafiltered extract of veal thymus; it has a cytorestaurative and immunomodulatory action, which has demonstrated its effectiveness in different risk groups, within which elder people occupy a special place. In the current national and international epidemiological situation its inclusion in the protocols of action is significant. The use of this medication in a vulnerable group, such as elder people, represents a hopeful horizon as progress is made in the production of safe and effective national vaccines.

Palavras-chave : immunity; Biomodulin T.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )